Cannabinoids for the treatment of neuropathic pain: clinical evidence
- PMID:18183533
Cannabinoids for the treatment of neuropathic pain: clinical evidence
Abstract
Neuropathic pain is a worldwide epidemic that occurs in 3 to 8% of individuals in industrialized countries and is often refractory to existing treatments. Drugs currently available to target neuropathic pain are, at best, moderately effective and include antidepressants, gabapentin, NMDA receptor antagonists, as well as other anticonvulsants, all of which are limited by their adverse-effect profiles. Cannabinoid drugs are emerging as a promising class of drugs to treat neuropathic pain and have been tested for analgesic effects in a range of chronic pain conditions. Data show that cannabinoids are often effective in individuals with refractory pain receiving concomitant analgesic drugs. Clinical studies on cannabinoids for the treatment of neuropathic pain are reviewed, focusing on clinical trials published within the last five years. Data from large, well-controlled studies show that cannabinoids are moderately effective in reducing chronic pain and that side effects are comparable to existing treatments, suggesting that cannabinoids can play a useful role in the management of chronic pain. Like other drugs for neuropathic pain, cannabinoids have a dose titration that is limited by psychoactive side effects. The development of cannabinoid drugs to target neuropathic pain with improved therapeutic ratios will depend upon the development of cannabinoid treatments with reduced psychoactivity.
Similar articles
- Management of neuropathic pain.Jensen TS, Finnerup NB.Jensen TS, et al.Curr Opin Support Palliat Care. 2007 Aug;1(2):126-31. doi: 10.1097/SPC.0b013e3282eeb45f.Curr Opin Support Palliat Care. 2007.PMID:18685353Review.
- Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.Pergolizzi J, et al.Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.Pain Pract. 2008.PMID:18503626
- Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.Rice AS, Farquhar-Smith WP, Nagy I.Rice AS, et al.Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):243-56. doi: 10.1054/plef.2001.0362.Prostaglandins Leukot Essent Fatty Acids. 2002.PMID:12052040Review.
- Reassessment of the role of cannabinoids in the management of pain.Beaulieu P, Ware M.Beaulieu P, et al.Curr Opin Anaesthesiol. 2007 Oct;20(5):473-7. doi: 10.1097/ACO.0b013e3282efd175.Curr Opin Anaesthesiol. 2007.PMID:17873600Review.
- [Use of cannabinoids in palliative medicine].Ernst G, Kongsgaard UE.Ernst G, et al.Tidsskr Nor Laegeforen. 2008 Apr 3;128(7):822-5.Tidsskr Nor Laegeforen. 2008.PMID:18389029Review.Norwegian.
Cited by
- The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J.Sánchez-Blázquez P, et al.Front Pharmacol. 2014 Jan 2;4:169. doi: 10.3389/fphar.2013.00169.Front Pharmacol. 2014.PMID:24427139Free PMC article.Review.
- The CB2 Agonist β-Caryophyllene in Male and Female Rats Exposed to a Model of Persistent Inflammatory Pain.Ceccarelli I, Fiorenzani P, Pessina F, Pinassi J, Aglianò M, Miragliotta V, Aloisi AM.Ceccarelli I, et al.Front Neurosci. 2020 Aug 18;14:850. doi: 10.3389/fnins.2020.00850. eCollection 2020.Front Neurosci. 2020.PMID:33013287Free PMC article.
- The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.Bíró T, Tóth BI, Haskó G, Paus R, Pacher P.Bíró T, et al.Trends Pharmacol Sci. 2009 Aug;30(8):411-20. doi: 10.1016/j.tips.2009.05.004. Epub 2009 Jul 14.Trends Pharmacol Sci. 2009.PMID:19608284Free PMC article.Review.
- Pruritus in autoimmune connective tissue diseases.Kim HJ.Kim HJ.Ann Transl Med. 2021 Mar;9(5):441. doi: 10.21037/atm-20-4894.Ann Transl Med. 2021.PMID:33842662Free PMC article.Review.
- In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM.Fiorenzani P, et al.Evid Based Complement Alternat Med. 2014;2014:596312. doi: 10.1155/2014/596312. Epub 2014 Jul 7.Evid Based Complement Alternat Med. 2014.PMID:25097659Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical